Risk of delays in research and development caused by COVID-19
First written in FY2020. 1 of 4 entries say "Mitigated", first in FY2021. Latest entry: FY2023.
The whole theme swung hardest in 2022: 4 of 20 companies on the "Worse" side.
2 other companies' latest entry also says "Dropped".
- FY2023DroppedAnnual reportThe risk of COVID-19-related delays to research and development and clinical trials, which had been disclosed previously, cannot be identified in the current description of business and other risks.
- FY2022RestatedAnnual report
「At this time, we believe that the impact of COVID-19 on the Company is limited. However, the ongoing COVID-19 pandemic may constrain the Company's research and development and clinical trials, potentially resulting in significant effects on its financial position and operating results due to delays in milestone revenue under license agreements and delays in approval as a new drug caused by delayed clinical trials.」
While the impact on the current fiscal year is considered limited, the risk remains that the spread of infection could delay research and development and clinical trials. - FY2021MitigatedAnnual report
「Based on the above, we believe that the impact of COVID-19 on the Company has been limited. However, if COVID-19 spreads further in the future and the situation becomes prolonged and more severe, research and development may not progress as planned, potentially resulting in extensions or cancellations of development. We believe that addressing this possibility is an important management issue for the Company.」
While the Company explained that the impact during the current fiscal year was limited due to measures such as remote work, the risk of research and development delays in the event of a wider or prolonged outbreak remains. - FY2020First statedAnnual report
「If COVID-19 spreads further in the future and the situation becomes prolonged and more severe, research and development may not progress as planned, potentially resulting in extensions or cancellations of development. We believe that addressing this possibility is an important management issue for the Company.」
The possibility of delays or cancellations in research and development due to the spread, prolongation or worsening of the infectious disease has been identified as a new risk.